Skip to main content
SpringerLink
Log in
Book cover

Sunlight, Vitamin D and Skin Cancer pp 39–52Cite as

Vitamin D Status and Cancer Incidence, Survival, and Mortality

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1268))

Abstract

Over the last several decades, extensive research on vitamin D and its role on cancer incidence, cancer survival (survival or mortality from cancer among individuals diagnosed with cancer), and cancer mortality (fatal cases occurring during the study period in an initially cancer-free population) has been conducted. A variety of study designs were implemented to explore vitamin D status, assessed by measuring sun exposure, vitamin D intake, and circulating 25-hydroxyvitamin D (25(OH)D) concentration. Although not many randomized controlled trials have examined the relationship between vitamin D and cancer incidence, observational studies have consistently shown a protective association between vitamin D and cancer incidence, especially for colorectal cancer. In addition, randomized controlled trials and most observational studies suggested that vitamin D plays a role in reducing cancer mortality. The potential benefit of vitamin D on cancer mortality may operate during the pre-diagnostic stages by affecting late-stage tumor progression and metastatic seeding, during the treatment phase by complementing or enhancing effects of therapies, or during the post-diagnostic stages. However, further studies are needed to confirm these conclusions, establish the optimal dosage and timing of vitamin D intakes for the most benefit, find which cancer types are affected, and understand the underlying mechanisms.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Peller S, Stephenson CS. Skin irritation and cancer in the United States navy. Am J Med Sci. 1937;194:326–33.

    Google Scholar 

  2. Apperly FL. The relation of solar radiation to cancer mortality in North American. Cancer Res. 1941;1:191–5.

    Google Scholar 

  3. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 1980;9:227–31.

    CAS  PubMed  Google Scholar 

  4. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990;19:614–22.

    CAS  PubMed  Google Scholar 

  5. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 1994;23:1133–6.

    CAS  PubMed  Google Scholar 

  6. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res. 1990;10:1307–11.

    CAS  PubMed  Google Scholar 

  7. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992;70:2861–9.

    CAS  PubMed  Google Scholar 

  8. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94:1867–75.

    PubMed  Google Scholar 

  9. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control: CCC. 2005;16:83–95.

    PubMed  Google Scholar 

  10. Grant WB. Solar ultraviolet irradiance and cancer incidence and mortality. Adv Exp Med Biol. 2014;810:52–68.

    PubMed  Google Scholar 

  11. Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 2006;26:2687–99.

    CAS  PubMed  Google Scholar 

  12. Mizoue T. Ecological study of solar radiation and cancer mortality in Japan. Health Phys. 2004;87:532–8.

    CAS  PubMed  Google Scholar 

  13. Chen W, Clements M, Rahman B, Zhang S, Qiao Y, Armstrong BK. Relationship between cancer mortality/incidence and ambient ultraviolet B irradiance in China. Cancer Causes Control: CCC. 2010;21:1701–9.

    PubMed  Google Scholar 

  14. Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer. 2007;120:1123–8.

    CAS  PubMed  Google Scholar 

  15. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, Giovannucci EL. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2004;13:1502–8.

    CAS  Google Scholar 

  16. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst. 2007;99:1120–9.

    CAS  PubMed  Google Scholar 

  17. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684–96.

    CAS  PubMed  Google Scholar 

  18. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma vitamin D and risk of colorectal cancer: the Japan public health center-based prospective study. Br J Cancer. 2007;97:446–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, Tjonneland A, Olsen A, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ (Clin Res Ed). 2010;340:b5500.

    Google Scholar 

  20. Woolcott CG, Wilkens LR, Nomura AM, Horst RL, Goodman MT, Murphy SP, Henderson BE, Kolonel LN, Le Marchand L. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2010;19:130–4.

    CAS  Google Scholar 

  21. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta-analysis. Am J Prev Med. 2007;32:210–6.

    PubMed  Google Scholar 

  22. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128:1414–24.

    CAS  PubMed  Google Scholar 

  23. McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, Cook NR, Eliassen AH, Zeleniuch-Jacquotte A, Agnoli C, Albanes D, Barnett MJ, Buring JE, et al. Circulating vitamin D and colorectal cancer risk: an international pooling project of 17 cohorts. J Natl Cancer Inst. 2018;111:158–69.

    PubMed Central  Google Scholar 

  24. Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D, Johnston S, Tenesa A, Campbell H, Dunlop MG. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32:2430–9.

    CAS  PubMed  Google Scholar 

  25. Toriola AT, Nguyen N, Scheitler-Ring K, Colditz GA. Circulating 25-hydroxyvitamin D levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2014;23:917–33.

    CAS  Google Scholar 

  26. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99:2327–36.

    CAS  PubMed  Google Scholar 

  27. Maalmi H, Ordonez-Mena JM, Schottker B, Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer (Oxford, England: 1990). 2014;50:1510–21.

    CAS  Google Scholar 

  28. Fedirko V, Riboli E, Tjonneland A, Ferrari P, Olsen A, Bueno-de-Mesquita HB, van Duijnhoven FJ, Norat T, Jansen EH, Dahm CC, Overvad K, Boutron-Ruault MC, et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2012;21:582–93.

    CAS  Google Scholar 

  29. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control: CCC. 1995;6:235–9.

    CAS  PubMed  Google Scholar 

  30. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 1993;2:467–72.

    CAS  Google Scholar 

  31. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 1996;5:121–6.

    CAS  Google Scholar 

  32. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control: CCC. 1998;9:425–32.

    CAS  PubMed  Google Scholar 

  33. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control: CCC. 2004;15:255–65.

    PubMed  Google Scholar 

  34. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol. 2004;89–90:533–7.

    PubMed  Google Scholar 

  35. Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 1998;58:442–7.

    CAS  PubMed  Google Scholar 

  36. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control: CCC. 1998;9:559–66.

    CAS  PubMed  Google Scholar 

  37. Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D, Virtamo J. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control: CCC. 2000;11:859–67.

    CAS  PubMed  Google Scholar 

  38. Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2002;11:719–25.

    CAS  Google Scholar 

  39. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control: CCC. 2000;11:847–52.

    CAS  PubMed  Google Scholar 

  40. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004;108:104–8.

    CAS  PubMed  Google Scholar 

  41. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796–804.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JA, Metcalfe C. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control: CCC. 2011;22:319–40.

    PubMed  Google Scholar 

  43. Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC, Gunter MJ, Key TJ, Eeles RA, Muir K, Neal D, Giles GG, et al. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. Int J Epidemiol. 2018;48:1416–24.

    Google Scholar 

  44. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, Lin Z. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol. 2014;140:1465–77.

    CAS  PubMed  Google Scholar 

  45. Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Cancer. 2015;137:2795–802.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Travis RC, Perez-Cornago A, Appleby PN, Albanes D, Joshu CE, Lutsey PL, Mondul AM, Platz EA, Weinstein SJ, Layne TM, Helzlsouer KJ, Visvanathan K, et al. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk. Cancer Res. 2019;79:274–85.

    CAS  PubMed  Google Scholar 

  47. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009;100:450–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013;37:666–70.

    CAS  PubMed  Google Scholar 

  49. Gupta D, Trukova K, Popiel B, Lammersfeld C, Vashi PG. The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer. PLoS One. 2015;10:e0119690.

    PubMed  PubMed Central  Google Scholar 

  50. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA, Giovannucci E. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011;6:e18625.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Brandstedt J, Almquist M, Manjer J, Malm J. Vitamin D, PTH, and calcium in relation to survival following prostate cancer. Cancer Causes Control: CCC. 2016;27:669–77.

    PubMed  Google Scholar 

  52. Mondul AM, Weinstein SJ, Moy KA, Mannisto S, Albanes D. Circulating 25-Hydroxyvitamin D and prostate Cancer survival. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2016;25:665–9.

    CAS  Google Scholar 

  53. Shui IM, Mondul AM, Lindstrom S, Tsilidis KK, Travis RC, Gerke T, Albanes D, Mucci LA, Giovannucci E, Kraft P. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015;121:1949–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2005;14:1991–7.

    CAS  Google Scholar 

  55. O’Brien KM, Sandler DP, House M, Taylor JA, Weinberg CR. The Association of a Breast Cancer Diagnosis With Serum 25-Hydroxyvitamin D Concentration Over Time. Am J Epidemiol. 2019;188(4):637–645.

    Google Scholar 

  56. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110:2772–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Rose AA, Elser C, Ennis M, Goodwin PJ. Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141:331–9.

    CAS  PubMed  Google Scholar 

  58. Vrieling A, Seibold P, Johnson TS, Heinz J, Obi N, Kaaks R, Flesch-Janys D, Chang-Claude J. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: influence of tumor characteristics and lifestyle factors? Int J Cancer. 2014;134:2972–83.

    CAS  PubMed  Google Scholar 

  59. Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res. 2014;34:1163–6.

    CAS  PubMed  Google Scholar 

  60. Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, et al. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Breast (Edinburgh, Scotland). 2016;25:69–74.

    CAS  Google Scholar 

  61. Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res: BCR. 2011;13:R74.

    CAS  PubMed  Google Scholar 

  62. Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O’Brien P, Han L, Rugo HS, Albain KS, Perez EA, et al. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat. 2015;150:605–11.

    CAS  PubMed  Google Scholar 

  63. Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). Cancer Med. 2014;3:693–701.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O’Reilly SE, Wilson CF, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29:3869–76.

    CAS  PubMed  Google Scholar 

  65. Vojdeman FJ, Madsen CM, Frederiksen K, Durup D, Olsen A, Hansen L, Heegaard AM, Lind B, Tjonneland A, Jorgensen HL, Schwarz P. Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. Int J Cancer. 2019;145:338–46.

    CAS  PubMed  Google Scholar 

  66. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, Albanes D. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006;66:10213–9.

    CAS  PubMed  Google Scholar 

  67. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Koenig KL, Kolonel LN, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:10–20.

    PubMed  PubMed Central  Google Scholar 

  68. Helzlsouer KJ. Overview of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:4–9.

    PubMed  PubMed Central  Google Scholar 

  69. Abnet CC, Chen Y, Chow WH, Gao YT, Helzlsouer KJ, Le Marchand L, McCullough ML, Shikany JM, Virtamo J, Weinstein SJ, Xiang YB, Yu K, et al. Circulating 25-hydroxyvitamin D and risk of esophageal and gastric cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:94–106.

    PubMed  PubMed Central  Google Scholar 

  70. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, Helzlsouer KJ, McCullough ML, Setiawan VW, Shu XO, Weinstein SJ, Weiss JM, Arslan AA, De Vivo I, Gao YT, et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:36–46.

    PubMed  PubMed Central  Google Scholar 

  71. Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV, McCullough ML, Weinstein SJ, Kolonel LN, Purdue MP, Shu XO, Snyder K, et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:70–80.

    PubMed  PubMed Central  Google Scholar 

  72. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, Weinstein SJ, McCullough ML, Purdue MP, Shu XO, Snyder K, Virtamo J, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:81–93.

    PubMed  PubMed Central  Google Scholar 

  73. Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U, Maskarinec G, Rothman N, Shu XO, Stevens VL, Zeleniuch-Jacquotte A, Albanes D, et al. Circulating 25-hydroxyvitamin D and risk of non-Hodgkin lymphoma: cohort consortium Vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:58–69.

    PubMed  PubMed Central  Google Scholar 

  74. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Cochrane BB, et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomark Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2012;21:82–91.

    CAS  Google Scholar 

  75. Toriola AT, Surcel HM, Calypse A, Grankvist K, Luostarinen T, Lukanova A, Pukkala E, Lehtinen M. Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer (Oxford, England: 1990). 2010;46:2799–805.

    CAS  Google Scholar 

  76. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, Feldman BS, Pan A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ (Clin Res Ed). 2014;348:g1903.

    Google Scholar 

  77. Weinstein SJ, Mondul AM, Yu K, Layne TM, Abnet CC, Freedman ND, Stolzenberg-Solomon RZ, Lim U, Gail MH, Albanes D. Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival. Eur J Epidemiol. 2018;33:1087–99.

    PubMed  PubMed Central  Google Scholar 

  78. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control: CCC. 2012;23:363–70.

    PubMed  Google Scholar 

  79. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007;25:479–85.

    CAS  PubMed  Google Scholar 

  80. Liu Y, Chen W, Hu ZB, Xu L, Shu YQ, Pan SY, Dai JC, Jin GF, Ma HX, Shen HB. Plasma vitamin D levels and vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer. Chin J Cancer Res (Chung-kuo yen cheng yen chiu). 2011;23:33–7.

    CAS  Google Scholar 

  81. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, Asomaning K, Hollis BW, Lynch TJ, Wain JC, Giovannucci E, Christiani DC. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5596–602.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Vashi PG, Edwin P, Popiel B, Gupta D. The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer. BMC Cancer. 2015;15:1012.

    PubMed  PubMed Central  Google Scholar 

  83. Anic GM, Weinstein SJ, Mondul AM, Mannisto S, Albanes D. Serum vitamin D, vitamin D binding protein, and lung cancer survival. Lung Cancer (Amsterdam, Netherlands). 2014;86:297–303.

    Google Scholar 

  84. Cheng TY, Neuhouser ML. Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction. Cancer Causes Control: CCC. 2012;23:1557–65.

    PubMed  Google Scholar 

  85. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Whitaker L, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009;27:5439–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Bade B, Zdebik A, Wagenpfeil S, Graber S, Geisel J, Vogt T, Reichrath J. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One. 2014;9:e112863.

    PubMed  PubMed Central  Google Scholar 

  87. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, et al. Association of vitamin D Levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol. 2016;34:1741–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O’Reilly EM, Fuchs C, Innocenti F, Venook AP. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst. 2014;106

    Google Scholar 

  89. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777–83.

    CAS  PubMed  Google Scholar 

  90. Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer. 2014;111:976–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380:33–44.

    CAS  PubMed  Google Scholar 

  92. Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D supplements and Total Cancer incidence and mortality: a Meta-analysis of randomized controlled trials. Ann Oncol: official journal of the European Society for Medical Oncology. 2019;30:733–43.

    CAS  Google Scholar 

  93. Martinez ME, Giovannucci EL, Colditz GA, Stampfer MJ, Hunter DJ, Speizer FE, Wing A, Willett WC. Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst. 1996;88:1375–82.

    CAS  PubMed  Google Scholar 

  94. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    PubMed  Google Scholar 

  95. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Hanseul Kim & Edward Giovannucci

  2. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Edward Giovannucci

  3. Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA

    Edward Giovannucci

Authors
  1. Hanseul Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Giovannucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Giovannucci .

Editor information

Editors and Affiliations

  1. Center for Clinical and Experimental Photodermatology and Department of Dermatology, Saarland University Medical Center, Homburg, Germany

    Jörg Reichrath

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kim, H., Giovannucci, E. (2020). Vitamin D Status and Cancer Incidence, Survival, and Mortality. In: Reichrath, J. (eds) Sunlight, Vitamin D and Skin Cancer. Advances in Experimental Medicine and Biology, vol 1268. Springer, Cham. https://doi.org/10.1007/978-3-030-46227-7_3

Download citation

Publish with us

Policies and ethics

Search

Navigation